FINNENCE ▪ THE WIRE FILE
THE WIRE · № 81928
News■ Unclear/unknown
OrbiMed lève 3 milliards de dollars auprès de fonds de capital-investissement mondiaux et asiatiques.
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZE2 RECORDS
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
French-language duplicate of the OrbiMed $3B fundraise; no incremental information.
Duplicate of OrbiMed fundraise, no new information
CATALYST TO WATCH
None beyond original announcement
MAIN RISK
Redundant content, no market effect
FULL DISPATCH
NEW YORK, 15 octobre 2026 /PRNewswire/ -- OrbiMed, une société d'investissement mondiale de premier plan dans le secteur de la santé, est heureuse d'annoncer qu'elle a levé 3 milliards de dollars d'engagements pour deux nouveaux fonds de capital-investissement : OrbiMed Private...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST · LAST2026-10-15 11:30 UTCNewsOrbiMed lève 3 milliards de dollars auprès de fonds de capital-investissement mondiaux et asiatiques.CURRENT RECORD
2026-10-15 11:30 UTCNewsOrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.